Humoral Hypercalcemia of Malignancy with a Parathyroid Hormone-Related Peptide-Secreting Intrahepatic Cholangiocarcinoma Accompanied by a Gastric Cancer

Table 2

Reported cases of cholangiocarcinoma secreting PTHrP who are alive for more than half a year.

Number	Authors	Age	Reported year	Sex	Ca level	PTHrP	Therapy	Prognosis
(1)	Davis et al. [17]	54	1994	Male	16.4	5.2	FUDR + 5-FU	Survival (for 6 months)
(2)	Yamada et al. [4]	43	2009	Male	14.4	5.0	TAE + PTPE + GEM + S-1 + Radiation	Died (after 14 months)
(3)	Lim et al. [18]	63	2013	Male	12.1	6.7	CAP + CDDP + Radiation, second-line GEM	Died (after almost 1 year)
(4)	Our case	74	2016	Male	14.8	26.6	CDDP + GEM	Survival (after 1 year)

FUDR: floxuridine; 5-FU: 5-fluorouracil; GEM: gemcitabine; CAP: capecitabine; CDDP: cisplatin; TAE: transcatheter arterial embolization; PTPE: percutaneous transhepatic portal embolization; PTHrP reported by Lim et al. was measured 9 months after an ICC diagnosis; Ca level means corrected Ca.